INTRODUCTION
Pancreatic cancer is the fourth leading cause of cancer deaths in this country and has the lowest 5-year survival rate among all malignancies. 1 Pancreatic tumors are highly aggressive and resistant to most treatments. Gemcitabine has been used as a major chemotherapeutic choice for pancreatic cancer, but factors influencing individual variations in response to gemcitabine are not well defined. Recent developments in pharmacogenetics have shown that genetic variations in drug metabolism, drug resistance, and cellular response to genotoxic stress affect individual responses to cytotoxic therapies, and these variations may serve as novel prognostic markers for stratifying patients in clinical trials or for predicting response to cytotoxic therapy.
2,3
The DNA repair pathways responsible for the repair of gemcitabine-induced DNA damage are not clearly understood. 4 Gemcitabine inhibits DNA synthesis by targeting ribonucleotide reductase, which results in deoxyadenosine triphosphate depletion, causing DNA replication errors. 5 Gemcitabine is also incorporated into DNA and arrests DNA replication via a "masked chain termination" mechanism. 6 Both the mispaired bases and gemcitabinemodified DNA bases can be the substrates for postreplicative DNA mismatch repair (MMR) machinery. If MMR were responsible for the removal and repair of gemcitabine-induced DNA damage, one would expect deficient MMR to confer a better response to gemcitabine. Indeed, MMR-deficient cells were more sensitive in vitro to gemcitabine-mediated radiosensitization. 7 MMR also plays a key role in maintaining genome stability, so MMR deficiency could lead to genome-wide instability and aggressive tumor phenotypes through rapid accumulation of genetic alterations. However, the role of MMR in pancreatic cancer is not clear. Germline mutations or inactivation of MMR genes by promoter hypermethylation is uncommon in this disease. 8 Some investigators suggested that pancreatic cancers with MMR deficiency have characteristic histologic features and may have an improved prognosis, 9 but others found no association between MMR and long-term survival among patients with pancreatic cancer. 10 Our previous work showed that polymorphic variants of DNA homologous recombination genes (eg, RecQ1 and RAD54L) had a significant effect on the overall survival of patients with pancreatic cancer treated with preoperative gemcitabine and radiation.
11 RecQ1 has been reported to interact with DNA MMR proteins 12 , which raised the question of whether the effect of RecQ1 genotype on patient survival was related to DNA MMR capacities. The current study evaluated 15 single-nucleotide polymorphisms (SNPs) of eight MMR genes: exonuclease I (EXO1), mutL homolog 1 (MLH1), mutS homolog 2 (MSH2), mutS homolog 3 (MSH3), mutS homolog 6 (MSH6), postmeiotic segregation increased 1 (PMS1), three prime repair exonuclease 1 (TREX1), and tumor protein 73 (TP73). SNPs were selected if they met at least two of the following three criteria: (1) the minor allele frequency is greater than 5% among white patients, (2) nonsynonymous SNP or SNP occurs at the 3ЈUTR, 5ЈUTR, or the splicing site, and (3) SNPs have been associated with cancer risk or clinical outcome in previous investigations.
PATIENTS AND METHODS

Patient Recruitment and Data Collection
Our study involved 154 patients who, at the time of their diagnosis, had potentially resectable adenocarcinoma of the head of the pancreas and had not received any treatment for pancreatic cancer. All patients had been enrolled in one of the two phase II clinical trials (ID98-020 and ID01-341) of preoperative chemoradiotherapy that were conducted sequentially from February 1999 through June 2006, 13,14 with continuing observation through June 2008. A DNA sample was collected from 154 patients for genotyping assays. The protocols of these trials were approved by the institutional review board of The University of Texas M. D. Anderson Cancer Center (Houston, TX) and were conducted in accordance with all current ethical guidelines.
The patients from the ID98-020 trial (N ϭ 70) had received chemoradiotherapy with seven weekly intravenous (IV) infusions of gemcitabine (400 mg/m 2 IV over 30 minutes) plus radiation therapy (30 Gy in 10 fractions over 2 weeks). For the patients from the ID01-341 trial (N ϭ 84), chemotherapy consisted of gemcitabine (750 mg/m 2 ) and cisplatin (30 mg/m 2 ) given every 2 weeks for four doses. Chemoradiotherapy consisted of four weekly infusions of gemcitabine (400 mg/m 2 ) combined with radiation therapy (30 Gy in 10 fractions administered over 2 weeks) delivered 5 days per week. The same eligibility criteria for patient recruitment had been applied in both trials, and no significant difference in any clinical feature was observed between the two patient populations. 13, 14 Tumor response to therapy was evaluated by computed tomography scan before and after completion of the preoperative chemoradiotherapy. Tumor response was defined according to the Response Evaluation Criteria in Solid Tumors as partial response, stable disease, or progressive disease. Tumor resectability was defined by achievement of marginnegative resection. Postsurgical treatment or treatment received after tumor recurrence was not considered in this study. Overall survival and disease-free survival times were calculated from the date of enrollment on the protocol or date of tumor resection, respectively, to the date of death or date of last follow-up.
DNA Extraction and Genotyping
DNA was extracted from peripheral-blood lymphocytes of 127 patients and from paraffin sections of normal adjacent tissues of 27 patients with resected tumors (20 from the ID98-020 trial) using Qiagen DNA isolation kits (Valencia, CA). Normal and tumor tissues are expected to have the same genotype for these germline common polymorphic sequence variants. Genotyping used the mass spectroscopy-based MassArray method (Sequenom Inc, San Diego, CA). Twenty percent of the samples were analyzed in duplicate, with 100% concordance in genotype calling. The genes, nucleotide substitutions, function (such as encoding amino acid changes), reference SNP identification numbers, and reported allele frequencies of the 15 SNPs evaluated in this study are summarized in Table 1 .
Statistical Analysis
The distribution of genotypes was tested for Hardy-Weinberg equilibrium with the goodness-of-fit 2 test. The heterozygous and homozygous genotypes were collapsed in the analysis if the frequency of the homozygous mutant was low or if the homozygous and heterozygous genotypes had the same direction of effect (eg, both had reduced survival time compared with the referent group). The associations between genotypes and tumor response to therapy or tumor resectability were estimated with odds ratios using multivariable unconditional logistic regression with adjustment for all clinical factors, including sex, age, race, tumor size, preoperative treatment (ie, the two clinical protocols), and serum CA19-9 levels at diagnosis, as well as all 15 SNPs examined in this study. The overall survival time and disease-free survival time were estimated using the Kaplan-Meier method. The associations between genotypes and survival time were tested using the log-rank test. The median follow-up time was computed using censored observations only. The effect of genotypes on overall survival time were estimated using hazard ratios (HRs), and 95% CIs were estimated using the multivariate Cox proportional hazards regression model, with adjustment for tumor response and resectability and other clinical factors and all genotypes examined. The effect of genotype on disease-free survival was further adjusted for node status and tumor grade. All statistical testing was conducted with SPSS software version 15.0 (SPSS Inc, Chicago, IL). All tests were two-sided, and a P value of less than .05 was considered statistically significant.
We estimated the false-positive report probability (FPRP) for the observed statistically significant associations using the methods described by Wacholder et al. 15 Odds ratio and HR values of 2.0 to 4.0 were considered as a likely threshold values. The prior probability used was 0.25 for all SNPs. The FPRP value for noteworthiness was set at 0.2.
RESULTS
Patients' Characteristics and Genotype Frequencies
The patients' characteristics and tumors' clinical features are summarized in Table 2 . In the 154 patients included in the current study, age, race, sex, and tumor size were not significantly associated with overall survival in the univariable analysis. The primary tumor was surgically resected in 116 patients (75.3%), and nine of the 116 patients had margin-positive resection (7.7%). At the end of our study (June 2008), 117 (76%) of the 154 patients had died. The median follow-up time was 49.9 months for the patients still alive. The median survival time (MST) of the 154 patients was 21.7 months (95% CI, 17.7 to 25.6 months). The factors that significantly associated with reduced overall survival time included poor tumor differentiation, serum CA19-9 level at diagnosis more than 47 units/mL, unresected tumor, increased tumor size after treatment, and node-positive resection.
Genotype frequencies of this patient population are presented in Table 1 . There was a statistically significant difference in the racial distribution of MLH1 Ϫ92GϾA, EXO1 V458M, and MSH3 P231P, with a higher frequency of the AA (90.1% v 41.7%), GG (18.4% v 5.4%), and GA/AA (30.8% v 10.2%) in nonwhites compared with that of whites, respectively.
Association of Genotypes With Tumor Response to Preoperative Therapy
Five SNPs were significantly associated with tumor response to preoperative therapy, and a combined effect of the five genotypes was observed (Table 3 ). The effects of MSH2 IVS12-6TϾC, MSH3 P231P, TP73 Ex2ϩ4GϾA, and the combined genotype on tumor response were statistically significant after adjusting for clinical factors. The effects of TREX1 Ex14-460CϾT, TP73 Ex2ϩ4GϾA SNP, and preoperative treatment on tumor response were statistically significant after further adjusting for all SNPs examined. The FPRP was 0.183 and 0.240 for TREX1 Ex14-460CϾT and TP73 Ex2ϩ4GϾA, respectively, indicating noteworthiness for TREX1 but not TP73.
Association of Genotypes With Tumor Respectability
Six SNPs were significantly associated with tumor resectability in the univariable analysis (Table 4) . A significant combined genotype effect on the rate of margin-negative resection was observed. The effects of MLH1 IVS12-169CϾT, TP73 Ex2ϩ4GϾA, and the combined genotype were statistically significant after adjusting for clinical factors. The MLH1 and TP73 SNPs and tumor response to therapy remained as significant predictors for margin-negative resection after further adjusting for other SNPs. The FPRP for MLH1 and TP73 was 0.034 and 0.051, respectively, indicating noteworthiness for both SNPs. 
Associations of Genotype With Overall and DiseaseFree Survival
Nine SNPs had statistically significant effects (P Ͻ .05) and one had a borderline significant effect (P ϭ .05) on overall survival by log-rank test (Table 5) . A strong gene-dosage effect was observed when the 10 genotypes were analyzed in combination (Fig 1) . The MST decreased as the number of variant alleles increased. Five SNPs and the combined genotype remained as significant predictors for survival after adjusting for clinical factors (Table 5) . EXO1 R354H, TREX1 Ex14-460CϾT, TP73 Ex2ϩ4GϾA, and marginnegative resection remained as significant predictors for overall survival after further adjustment for other genotypes. The FPRP was 0.085 for EXO1, 0.009 for TREX1, and 0.046 for TP73, all indicating noteworthiness.
The combined genotype was a significant predictor for diseasefree survival among the 107 patients with R0 resection (Fig 1) . The MST could not be calculated for 13 patients with zero to one variant genotype because 10 patients were still alive; MST was 50.1, 22.9, and 13.9 months for those with two (n ϭ 34), three (n ϭ 36), and four to seven (n ϭ 24) adverse genotypes, respectively (P Ͻ .001). Carrying more than three adverse genotypes (HR ϭ 4.02; 95% CI, 1.15 to 14.1; P ϭ .03) and having poorly differentiated tumors (HR ϭ 2.06; 95% CI, 1.05 to 4.04; P ϭ .035) were the only significant predictors for disease-free survival in multivariable Cox regression models that included all clinical and genetic factors. None of the genotypes were significantly related to tumor grade (data not shown).
DISCUSSION
In this study, we found that SNPs of DNA MMR genes were significantly associated with tumor response to preoperative therapy, tumor Abbreviations: MST, median survival time; HR, hazard ratio.
‫ء‬ P values were calculated using the log-rank test. †HRs were adjusted for all clinical factors. ‡HRs were adjusted for all clinical and genetic factors.
resectability, and overall and disease-free survival of patients with potentially resectable pancreatic adenocarcinoma who had received preoperative chemoradiotherapy, thus validating our hypothesis. A strong combined-genotype effect on each clinical end point was observed. These observations, for the first time, to our knowledge, demonstrated a potential value of DNA MMR gene variants as both predictors for clinical response to chemoradiotherapy and prognostic factors for survival in patients with resectable pancreatic cancer. Of the 15 SNPs evaluated, EXO1 R354H, MLH1 IVS12-169CϾT, TREX1 Ex14-460CϾT, and TP73 Ex2ϩ4GϾA showed significant associations with clinical outcome after adjusting for all clinical and other genotypes. MSH2 G322D, MSH2 IVS12-6TϾC, MSH3 P231P, and PMS1 Ϫ4GϾC showed significant associations after adjusting for clinical factors but borderline significant associations after further adjusting for other genotypes. It is known that gemcitabine incorporation causes DNA replication arrest, and ATR/Chk1 signaling pathway plays a crucial role in cellular response to stalled DNA replication fork. 16, 17 Cells that lack ataxia-telangiectasia mutated and rad3-related (ATR) or checkpoint kinase 1 (Chk1) genes have been shown to be more sensitive to gemcitabine.
17, 18 Our previous study in the same patient population has shown a significant combined genotype effect of ataxia telangiectasia mutated (ATM), ATR, Chk1, and checkpoint kinase 2 (Chk2) on overall survival. 19 The observed effects of MSH2, TREX1, TP73, and EXO1 genotypes in the current study may all be associated with interference of the ATR/Chk1 signal pathway. For example, MSH2 not only plays a key role in recognizing the base-base mismatches and initializes the MMR process, 20 but also directly interacts with ATR to regulate the DNA damage response. 21 TREX1 is a major 3Ј to 5Ј exonuclease in mammalian cells, and TREX1 deficiency resulted in intracellular accumulation of single-stranded DNA and chronic activation of the DNA damage response ATM/Chk2 network.
22 TREX1-null cells failed to phosphorylate Chk1 after cells were exposed to hydroxyurea, which suggests a compromised ATR signaling pathway function.
22 TP73 is a member of the p53 family of transcription factors involved in cellular responses to stress and development.
23 TP73 accumulation was shown after a variety of chemotherapeutic agents, 24 but it was not induced in MMR-deficient cells after cisplatin.
25 EXO1 is a 5Ј to 3Ј exonuclease that directly interacts with MSH2, MSH3, and MLH1 and possibly acts in MMR by catalyzing 5Ј to 3Ј excision and by stabilizing higher-order complexes of MMR proteins. [26] [27] [28] Previous studies have shown that P73 is a target of Chk1 kinase, 29 and EXO1 stability is dependent on ATR kinase. 30 It is conceivable that MSH2 deficiency may lead to failure in DNA damage recognition and activation of ATR/Chk1 machinery. TREX1 and TP73 deficiency may further compromise the ATR/Chk1 signaling transduction. EXO1 deficiency would reduce the MMR capacity. Thus cells with these variant genotypes may not be able to undergo apoptosis in response to gemcitabine-induced DNA damage, which is a critical determinant of the efficacy of cytotoxic therapies. The poor response to therapy would result in reduced tumor resectability or persistent micrometastatic disease, which in turn contribute to reduced overall survival and disease-free survival.
The EXO1 R354H and MSH2 G322D are nonsynonymous SNPs that result in replacement of amino acids, in turn, possibly affecting the protein functions. The TREX1 Ex14-460CϾT and TP73 Ex2ϩ4GϾA SNPs are located at 3ЈUTR and 5ЈUTR, respectively. Although these sequences do not translate into proteins, the 3ЈUTR may contain sequence motifs crucial for the regulation of transcription, mRNA stability, and cellular location of the mRNA or the binding of microRNA. 31 The 5ЈUTR may contain regulatory sequences that serve as binding sites for proteins or affect the mRNA's stability and translation. 32 Further investigations into the functional significance of the MMR gene SNPs and the genotype-phenotype associations are warranted.
MLH1 is frequently mutated in hereditary nonpolyposis colorectal cancer. The exact role of MLH1 in MMR is not fully understood. 33 Tumors with inactivated MLH1 gene by loss of heterozygosity or promoter methylation show higher rate of microsatellite instability and higher tendency for lymphocytic infiltration or poor differentiation. [34] [35] [36] [37] The fact that MLH1 SNP was significantly associated with tumor resectability but not with tumor response or survival in this study suggests that pancreatic tumors with MLH1 variant alleles may have some unidentified pathologic characteristics. Further study is required to fully understand the role of MLH1 in pancreatic cancer. Combined effect of 10 genotypes on (A) overall survival and (B) disease-free survival among patients with pancreatic cancer. The Kaplan-Meier method was used to assess the combined effect of the EXO1 R354H GA/AA, EXO1 P757L CT/TT, MSH2 G322D GA/AA, MSH2 IVS12-6TϾC TC/CC, MSH3 P231P GA/AA, MSH6 G39E GA/AA, PMS1 Ex1-4GϾC GC/CC, TREX1 K125Q AC, TREX1 Ex14-460CϾT CC, and TP73 Ex2ϩ4GϾA AA genotypes on overall and disease-free survival. The numbers from 0 to 7 indicate the numbers of at-risk genotypes. P value from log-rank test was less than .001 for both A and B.
Although some SNPs in this study showed weak effect individually, the combined-genotype effect on each clinical end point was dramatic, suggesting that these genes act in concert, and the combined action of many genes may have a greater influence on the phenotype, (eg, the chance of survival) than individual SNPs. Identification of a panel of genetic markers that can be applied in the clinic to help predict tumor response to therapy, tumor resectability, and patient survival would be the ultimate goal of this research. In addition, some of the genes identified in these studies may serve as a therapeutic target to improve the efficacies of cytotoxic agents in cancer treatment. 38, 39 Our study was conducted in a relatively homogenous patient population with an adequate sample size. Although some differences in the clinical outcomes were observed for patients who were enrolled on the two different protocols, this was partially explained by a sampling bias. For patients enrolled in ID98-020 (N ϭ 70), DNA was extracted from 50 blood samples and 20 paraffin sections from normal adjacent tissue of resected tumors when blood sample was not available, which resulted in a higher tumor resection rate (87%) than the true resection rate of 74% in this trial.
14 To overcome this bias, we have adjusted for this variable (preoperative treatment) in the multivariable models. Some of the associations we observed could have occurred by chance, although the results of FPRP test indicate noteworthiness for most SNPs that are significant in the multivariable models. Our observations need to be confirmed in separate patient populations. If confirmed, these findings may provide opportunities for discovery of novel markers that can help in choosing therapy for pancreatic cancer and in predicting a patient's tolerance and response to treatment, tumor resectability, and overall clinical outcome.
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